Aurinia Pharmaceuticals Inc Stock News

Aurinia Pharmaceuticals (AUPH) reversed an earlier decline and is now up 3.4% after a report indicated Biogen (BIIB) could potentially look to target the company.Aurinia (AUPH) was

These three stocks are poised for a major breakout in 2022.

These three stocks are poised for a major breakout in 2022.

VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (the “Company”) today announced that members of the management team will participate in two upcoming virtua

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) concluded the trading at $22.69 on Wednesday, December 22 with a rise of 0.62% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $22.55 and 5Y monthly beta was reading 0.66 with its price kept floating in the Aurinia Pharmaceuticals Inc. (AUPH) Is Waiting On The Launchpad To Make A Splash. Read More »

Parametric Portfolio Associates LLC grew its holdings in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) by 24.5% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 32,796 shares of the biotechnology companys stock after acquiring an additional 6,462 shares during the period. Parametric Portfolio Associates LLCs holdings in [] The post Parametric Portfolio Associates LLC Acquires 6,462 Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) appeared first on ETF Daily News .

Investors need to pay close attention to CorMedix (AUPH) stock based on the movements in the options market lately.

During the last session, Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)s traded shares were 2.65 million, with the beta value of the company hitting 0.68. At the end of the trading day, the stocks price was $19.67, reflecting an intraday loss of -1.01% or -$0.2. The 52-week high for the AUPH share is $33.97, that puts it down Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) Continues To Thrive In 2021, As Its Stock Is Up 42.23% Year-To-Date Read More »

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) Director Jill Leversage purchased 1,600 shares of Aurinia Pharmaceuticals stock in a transaction that occurred on Monday, December 13th. The shares were acquired at an average price of $20.04 per share, with a total value of $32,064.00. The purchase was disclosed in a legal filing with the SEC, which is []

Wall Street brokerages forecast that Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) will post earnings per share (EPS) of ($0.25) for the current quarter, according to Zacks. Five analysts have provided estimates for Aurinia Pharmaceuticals earnings. The lowest EPS estimate is ($0.27) and the highest is ($0.22). Aurinia Pharmaceuticals posted earnings of ($0.05) per share during the []

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP)s stock had its buy rating reaffirmed by stock analysts at Jefferies Financial Group in a note issued to investors on Wednesday, AnalystRatings.com reports. A number of other equities research analysts have also commented on the company. Royal Bank of Canada upped their price target on Aurinia Pharmaceuticals from $23.00 to $34.00 []

Aurinia Pharmaceuticals (AUPH) has been in the news for a couple of reasons over the past few weeks. First there were rumors the biotech was a bolt on accusation ta…

Oppenheimer upgraded shares of Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) from a market perform rating to an outperform rating in a research note issued to investors on Friday morning, Analyst Ratings Network reports. Oppenheimer currently has $31.00 target price on the biotechnology companys stock, down from their previous target price of $33.00. Other equities research analysts have []

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP)s share price gapped up before the market opened on Thursday . The stock had previously closed at $20.83, but opened at $21.88. Aurinia Pharmaceuticals shares last traded at $21.18, with a volume of 48,433 shares changing hands. Several brokerages recently issued reports on AUPH. Oppenheimer raised shares of Aurinia Pharmaceuticals []

The stock price of Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) increased by over 8% this past week. This is why it happened.